Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125515771 | 12551577 | 1 | I | 201606 | 20160706 | 20160713 | 20160713 | EXP | US-UNITED THERAPEUTICS-UNT-2016-010988 | UNITED THERAPEUTICS | 39.24 | YR | F | Y | 53.52000 | KG | 20160713 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125515771 | 12551577 | 1 | PS | REMODULIN | TREPROSTINIL | 1 | Subcutaneous | 0.118 ?G/KG, CONTINUING | U | U | 2100701 | 21272 | .118 | UG/KG | INJECTION | ||||
125515771 | 12551577 | 2 | C | ADCIRCA | TADALAFIL | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125515771 | 12551577 | 1 | Pulmonary arterial hypertension |
125515771 | 12551577 | 2 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125515771 | 12551577 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125515771 | 12551577 | Death | |
125515771 | 12551577 | Malaise |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125515771 | 12551577 | 1 | 20131106 | 0 |